Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The splitting of the Units has occurred, and today the new symbols are trading as follows:
NVAC $9.70 - $9.93 (0 trades so far)
NVACW $0.24 - $0.25 (141K trades)
NVACR $0.23 - $0.30 (0 trades so far)
From post #16, these were my calculations:
CDC admits prior infection with COVID created a better immunity to the Delta Variant than vaccination.
When you think "Natural Immunity", think of the best way to prove that one has natural immunity, that one actually had a COVID infection.
Think of a way to detect "Neutralizing Antibodies", which are the end result of a natural infection (as well as the end result desired by vaccination).
And then think of how one could show that they have Neutralizing Antibodies, and at what level.
Think "Immunopass".
Anyone know hw many shares of Axim Johnny H owns?
(As an aside, I just noticed that less than 11,000 shares traded on Friday).
I don't foresee an appeal of any kind. I can't see how Immunopass wouldn't get its EUA. With almost 2 dozen antibody test kits getting their EUAs in November and December of last year, what reasoning would the FDA give for refusing Immunopass?
Why would the FDA put out that News Release on 11/15/21?
I feel the EUA is coming, but that the FDA is delaying its approval to let society catch up.
I still put my prediction as somewhere between 2/2/22 and 2/20/2022.
Godspeed.
When you can, you might as well have fun doing it.
I played a few SPACs in 2021, and I feel I have learned a lot (from my mistakes).
Buying on "rumor" is what is occurring now. Selling on the "News" is what occurs very quickly soon after the merger/acquisition target is announced.
Also, the splitting up of a unit into its parts, to be traded separately, is a good sign that the "news" is coming soon. The Warrants and the Rights really have no value at this time, but they will once the target is secured. Splitting up the units after an announcement is just too complicated.
I think that the PR from two days ago speaks volumes. I believe a target has been found.
If you look at the chart of a typical SPAC, you will see that the best time to sell is immediately after the target of that SPAC is announced.
After that initial pop, the stock continues to slowly drop in value.
Fortunately, the stock never goes back to its pre-target announcement days, but the best profits can be found right after the acquisition news is PR'd.
Now, with the Units being split into their pieces, and 2 of the 3 pieces essentially worthless until a merger occurs, I'm thinking that is coming real soon.
I'm just going to sit tight till that something happens.
Godspeed.
38110
I checked the FDA's website again just a few moments ago.
Still no new medical devices given an EUA since 12/17/2021.
That is now officially over 1 month ago.
I can't help but feel that Immunopass is next, and that the FDA is just waiting for the right time to approve it.
Politics.
But just tonight, Biden's FEDERAL mandate to have all FEDERAL Employees vaccinated was put on a pause by a Federal Court.
https://www.govexec.com/workforce/2022/01/federal-court-orders-nationwide-pause-bidens-federal-employee-vaccine-mandate/361010/
....just hoping the waning of the interest in vaccinations will soon lead to a surge in the interest in antibody titers........
Thinking along the lines of the dividing up of units that will occur after the close of business tonight:
After the split, there will be a price for a share, = X
The price for a Right should then be no greater than .1X (That is, 1/10th of the price of a future share)
The price of a warrant has to be X - $11.50, since why would you pay for a warrant to buy a share in the future for $11.50, if you could buy that share today for X?
Since, as of today, X - 11.50 would be a negative number, we must leave the warrants out of the equation in order for the equation to make any sense (that is, the Warrants will be worth almost nothing after the unit is split into its parts. Let's assign it a value of .01).
Therefore, using the following equation, where NVACU is the current unit price today of $10.10:
NVACU = NVAC + NVACR + NVACW
$10.10 = X + .1X +.01
Solving for X, which should be the price of a share of NorthView comes next week, we see roughly:
NVAC = $9.18
NVACW = $.01 (just to give it a minimum value)
NVACR = $.91
So, I am going to say that, since NVACR only has value when a business relationship is consummated sometime in the future, then comes end of next week, the split up units will be trading more likjely as follows:
NVAC.......... = $9.80 to $9.95
NVACW....... = $0.01 to $0.05
NVACR....... = $0.30 to $0.40
LOL....let's see how far off I am.
35440
....and "We The AXIM Investors" appreciate all of your efforts.
I'll keep them in mind, but I did go all in with NVACU these last 2 weeks, so capital is tied up for a bit.
I see NorthView as a quick in and out, with the possibility to double or triple the investment in a very short time.
I have no intentions of holding a share, a warrant, or a right more than 3 or 4 days after they PR a target.
Really, with the amount of shares I picked up, I should be able to get out in less than a day.
Good luck with all your investments.
NOW I'M JEALOUS!
Are you saying you went to 45's Rally the other day? (I thought that was Florence, Arizona?).
And I thought I watched the whole thing....like 3 or 4 times, because I kept rewinding....but the part about antibodies must have gone right over my head.
His Rallies truly are entertaining.
Congratulations.....and I am jealous.
Personally I am more anxious to attend one of those rallies than I am to see Immunopass get its EUA.....
....ok....that's an exaggeration.....but the rally comes in as a close second.........
Godspeed
Stressful times.
Best of luck to all.
Look on the bright side - the pps can't go too much lower, can it?
I mean......it certainly can't go into negative numbers.....?.....!....?
My apologies, those years (2020 and 2021) were so clear in my previous post, I don't know how that got past me.
Then again, August 2022? Are you looking into a crystal ball, because that's like 7 months in the future........
Yes, there is. Peter's involvement with NorthView is completely transparent.
A thought occurred to me yesterday:
Did you say that you were watching NorthView from about April 2021? I found this in the media:
If you are averaged in around a quarter, you really aren't doing all that badly. I don't think it is ever possible to get anything "totally right."
Personally, I am overseeing a large number of shares, but the best I have been able to average down to is a hair below 50 cents.
Talk about being in the red! My average is so deep into the red it is basically burgundy heading into a reddish-purple.
Kind of the way I like my meat cooked - drop it on the grill on one side for 10 seconds, flip it over for another 10 seconds, then slap it on a plate and put any left over juices in a sippy cup - but this is certainly not the color I like to see in investing.
Patience. Time will tell......
Agreed, and to say it another way, if there was no Immunopass what-so-ever, buying at these prices just in consideration of the DED line would make sense.
The DED line has, on its own, the ability to be a (multi) billion dollar driver.
At close of business on January 21, 2022, the Units of NVACU were split as follows:
Before COB on 1/21/2022:
NVACU = the "Unit", which consisted of 1 share, 1/2 warrant, and 1/10th Right
After COB on 1/21/2022:
NVAC = Common Share
NVACW = A Warrant, 1 Warrant issued for every 2 units owned, no warrants for a single (or odd numbered) unit, warrants are for the future purchase of a share of NVAC @ $11.50, regardless of the market price.
NVACR = Rights, 1/10th of a Right issued for every unit. Apparently, there will be shares issued in 10ths, as I have not seen a restriction as to ownership of fractions of units in lots less than 10 units. The Right is for 1/10th of a common share upon the successful consummation ("joining") of a business relationship.
By buying units in lots of 10, an investor will not lose in the case of a half warrant (since the units purchased are in even numbers), AND the investor will NOT wind up with any fractional shares upon business consummation.
With yesterday's Press Release, stating that comes the close of business this Friday (1/21/2022), the NorthView "units" currently being sold (NVACU) will be split into three pieces and thereafter trade as three separate entities (NVAC for the shares portion, NVACR for the Rights portion, and NVACW for the Warrants portion), I shot off my last round of purchases, achieving a share level slightly more than I had originally expected.
Now it is just a matter of waiting for "the News" (ie: the "rumors" portion, for me at least, has come to a close).
Interestingly, the average share volume is currently being reported at 361,957 shares per day, with today's volume so far just at 6,479 shares (of which, a certain blind squirrel had a hand in 85% of them).
My thoughts are two-fold:
1. Splitting up the units into three separate pieces, each of which is to be traded separately, must be a sign that the SPAC is quickly moving forward (ie: a target has been found). CLEARLY, the warrants to buy NVAC at $11,50 have absolutely no value today, since even in tact entire units are trading way under that value ($10.10 per unit). The same is true of the Rights, which only kick in when NorthView consummates a deal of some sort. Currently, those Rights are worthless, especially when one considers that if a merger doesn't occur within 2 years, all of the $ collected by the SPAC must be returned, and the Rights will have absolutely no value. So my thoughts are, the only logic in splitting the units now into 3 separately tradeable entities, is that there is an event coming, in the very near future, that will make each separate entity worth trading (and THAT is most likely an announcement of an acquisition target).
2. Most of the time, when you split things up, the value of the pieces is greater than the value of the whole (think about how a car's parts are worth more than the car itself, or how after a stock split, the new sum of the parts are worth more than the original whole). Along those lines, anyone who just wanted to own Shares would have had (up unto close of business tomorrow) to buy entire units, and essentially "pay something extra" for the two other pieces (Rights and Warrants) which they didn't want. NOW, however, starting next week, anyone who wishes only to hold shares can (theoretically) sell off the Rights and/or Warrants that they are not interested in, and anyone who just wants Shares and nothing else now has the ability to acquire exactly what they want. Here to, in this situation, the sum total of the parts should ultimately turn out to be greater than the unit as a whole. In other words, the $10.10 spent on a unit today will have a (slightly) greater value when the parts are summed up next week (such as $10.15?, etc.).
If nothing else, the Press Releases shows progress moving forward, which is the whole purpose of the SPAC....to move forward and actually "buy" something.
35330
NorthView Acquisition Corp. announced today that, on January 21, 2022, the Company’s units will no longer trade as "a unit", which originally consisted of:
NVACU (the "U" meaning "Unit"):
1 share,
1/10th of a RIGHT to a share to be issued upon a merger,
1/2 of a WARRANT TO PURCHASE the stock at $11.50 (regardless of market price),
will after this Friday, now be split into and trade under the separate symbols:
Common Stock (NVAC),
Rights (NVACR)
Redeemable Warrants (NVACW),
https://www.globenewswire.com/news-release/2022/01/19/2369708/0/en/NorthView-Acquisition-Corp-Announces-Upcoming-Automatic-Unit-Separation.html
NorthView Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. The Company intends to focus its initial search on target businesses in the healthcare sector with an enterprise value of approximately $500 million to $2 billion.
They should use Greek Letters in their symbols, to bring back an old saying famously "coined" in one of Shakespeare's plays (Julius Caesar),
Crypto?
Hell no.
I just can't understand it, and if I can't apply logic to something, I couldn't possibly sleep at night.
Let everyone else make millions off of it, but I wouldn't give up a single night's sleep to be a part of it.
I could see investing everything I got into crypto, then waking up the next morning and realizing crypto was all just a dream....except, now....where did all my Schiff go?
Nope. I'd rather overthink things like AXIM, Empowered Diagnostics, NorthView Acquisitions, psychedelics, Cannabis stocks, Hydrogen Fuel Cells, etc.
At least I can put politics and logics into those things, and when they go down the tubes, I'm not standing there scratching my head trying to figure out how and why.
Yet another good day.
Just waiting for some fresh powder to become available next week.
Godspeed to all on this venture.
29760
Agreed, there is something very fishy going on, but when the opportunity presents itself, who can resist?
I guess it is just a matter of setting the number of shares that you wish to own just a tad bit higher, no?
Keeping in mind, "Never invest more than you can afford to lose", at these prices, I see AXIM as more than just a bargain.
With your 21 years+ experience, I'm sure you can spot those who pretend to generously give of their expertise, but seek to take advantage of anyone who takes a bite.
Godspeed
Liking this new board!
It's like my own, online, AXIM/NVACU Diary, where I can say whatever I want, and if I am right, I can refer people back to this site some day in the future.
If I am wrong, well, no one will ever find this place.
LOF'ingL!
26249
May I call your attention to post #2622:
The goal I see here, as it relates to a SPAC, is to buy at a certain price and be prepared for the SPAC to remain there, at that very same price, until a target is announced.
In a strong sense, buying a SPAC is like putting your $ in a bank. After all, the SPAC has minimal expenses, and the funds "deposited" into a SPAC are held with the specific purpose of buying something.
Trump's SPAC, DWAC (Digital World Acquisition Corp.) is moving up, but that is because of the growing expectation that DWAC is going to scoop up all the "fake news" networks when Truth Social comes out (2/21/2022) and the stock values of all of those other media stations start to tank.
In essence, DWAC has already named its target(s) even before it actually and publicly announces what its target will be.
Damn, I am thinking $7 to $14 pps after EUA. You are going to be "happy" with $2.
I'm certain you will get what you are hoping for extremely soon after the EUA.
My target might have to wait till end of year.
Keep a wary eye on this one.
https://www.globenewswire.com/news-release/2021/12/23/2357419/0/en/NorthView-Acquisition-Corp-Announces-Closing-of-189-750-000-Initial-Public-Offering-Including-Full-Exercise-of-Underwriter-Over-Allotment-Option.html
As Peter O'Rouke is both on the Board at AXIM Biotechnologies, and a member of NorthView Sponsor I, LLC (which owns 4,743,750 shares of NVACU), I think this is worth watching.
Is NorthView Acquisition Corp.'s initial purpose to bring AXIM's manufacturing partner (Empowered Diagnostics) public?
Once the Special Purpose Acquisition Corp. accomplishes that first phase, where would it go from there?
Acquire other manufacturing companies?
Merge with AXIM Biotechnologies?
Then what?
My gut tells me that AXIM will get its long-awaited approval (EUA) for Immunopass sometime in early February, 2022. (02/02/2022, 02/20/2022, 02/22/2022?)
I don't think it is a coincidence that Mr. O'Rouke has connections to both AXIM and NVACU, and that NVACU had its IPO just a few weeks ago (12/23/21).
Peter O'Rouke looks like a brilliant man with the ability to see the future.
Can't hurt to ride along on those coat tails.
I also like the offer: 1 unit = 1 share of NVACU, plus 1/2 warrant to buy NVACU at $11.50, plus 1/10th of a share of NVACU once an acquisition is consummated.
I've been accumulating @ $10.10 since 1/10 in lots of 10 shares.
Let's see where this one goes.
19253
My thoughts are more along the lines of 3 more weeks.
As early as Feb 2nd to as late as Feb 20th, or any where in between, the key turning point being the announcement of an EUA for Immunopass.
I myself am currently planning accordingly.
Godspeed.
So if anyone is really pondering the likelihood of Immunopass getting its EUA, consider this:
On 11/15/21, the FDA put out a news release stating that they would focus their efforts on test kits that could be done at home AND that can be mass produced.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-updates-test-policies-help-ensure-accuracy-and-reliability-tests-and
Three days later, AXIM put out a Press Release complimenting what the FDA said and linking Immunopass to the FDA's statement.
https://www.globenewswire.com/news-release/2021/11/18/2337634/33692/en/AXIM-Biotechnologies-Applauds-FDA-s-Recent-COVID-19-Test-Policies-to-Support-Rapid-Neutralizing-Antibody-Tests.html
Now, here is the funny part: After the November 15th announcement, the FDA continued to approve test kits that couldn't be done at home, that needed laboratory technician interpretation, and that weren't being massed produced, etc., and another dozen test kits were approved over the next month, between that news release (11/15/21) and 12/17/21.......and then nothing.....
Today is one month (31 days) since the FDA's last approval (12/17/21), and over 2 months since the FDA made their proclamation (11/15/21), and NOTHING approved that even comes close!
I believe we are now in overdue territory.............
Out of the 2 responses you received to your question, I believe mine was more fun, but the reality that you should derive from both answers is that it is absolutely impossible to guess based on the variables that exist at the present time:
Does Immunopass gets its EUA?
Will society embrace antibody testing to replace testing for the presence of the virus?
Will society replace "Vaccine Passports" with "Neutralizing Antibody Passports"?
What is the potential Worldwide demand for Immunopass?
How much will Immunopass cost, and how often will an individual use an immunopass test kit per year? per month?
Will the Federal Government make Immunopass test kits available to the population, "free of charge" (as they are currently doing now for COVID test kits)?, and/or will insurance companies be required to reimburse individuals for the cost of their test?, etc.
Too many variables, each one of which has a wide range of values.
I revert back to my original statement:
Truly, your guess is as good as anyone else's, and depends on your beliefs and expectations:
1. If Immunopass does for AXIM what the CBD Gum did 5 years ago (if history repeats itself), then almost $20 per share.
2. If Immunopass is a "multi-billion dollar driver" as suggested in the interview of August, 2021,
...if dreams mean anything, make that 2/2/22 for the EUA.
Wed 2/2/22.
Now that even seems more logical.
The Sunday 2/20/22 appears to be a "week of" and for something else that I have been working on.
Godspeed and Good Night.
Jack of all trades, Master of none, but I do enjoy sorting through facts to come to a logical conclusion.
Rest assured, we are all here because none of our trading history has been exemplary. Best thing is to keep learning from our mistakes.
As for my daughter, I just try to get her to think systematically and logically, and to apply that process when ever and where ever possible. LOL, the one idea she gets the best: MOST of the time, if there are multiple choice answers, you can eliminate the "absolutes" such as All, Every, Never, etc., since almost nothing is ever 100%.
As I mentioned earlier this week, I am fully loaded (and then some) with AXIM and have lifted and shifted my focus and am now doing some intense DD on another company (and accumulating accordingly), but I am keeping an eye on AXIM and the AXIM board, as I believe things are getting close.
Since my new focus is an offshoot of this one, I will mention it here by the end of next week, if my DD pans out accordingly.
AS FOR AXIM, Friday's late day action was interesting, but as we have seen AXIM on a few dead cat bounces in the recent past, I'm not doubting that this is just another one of those DCBs. I still think it is too early for any momentum related to the EUA, as I still see 2/20/2022 as the final line in the sand (just a gut feeling, nothing else).
INTERESTING thing is that Monday (1/17/22) will be exactly 1 entire month that the FDA has NOT issued an EUA for a medical devise (12/17/21),
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2
AND that ALL of the approvals in November and December were for antibody test kits, AND that ALL of those test kits require intervention by a trained lab technician, AND that the FDA's 11/15/21 News Release mentioned that they were going to shift their focus to mass produced, at home test kits.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-updates-test-policies-help-ensure-accuracy-and-reliability-tests-and
You see, as my theory goes, the FDA was knocking out all of those inferior test kits (that require intervention by a laboratory technician) because they had to, since they owed it to all those companies that did the hard work, and since approving any of them after Immunopass wouldn't make any sense (because Immunopass is so far ahead of the rest as to make them obsolete, eg: Immunopass is by far First-in-Class).
So as my theory goes, since the FDA has stopped knocking out those approvals, then the next one up must be.....Immunopass?
Funny how the approvals were coming in hot and heavy, and then suddenly a month without a single one.
The next question is.....what is the FDA waiting for?
....and the very funny thing is, that the thing that caught my attention and caused me to lift and shift focus away from AXIM, could actually be the answer to that question....
.....but I plan to discuss that a week from today.
OH, BTW, Monday is MLK Birthday celebration, so the markets are closed.
Godspeed.
So she scored a 96.7% today on her math exam.
One last thought for tonight:
The very last antibody test kit given an EUA by the FDA was on 12/17/21.
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2
I bring this up, because this coming Monday will be an entire month since any kind of a medical device EUA was issued.
In posts last year, I suggested that the FDA was knocking out all of those other, inferior antibody test kits, ALL of which require the intervention of a trained lab technician in order to get the results.
AXIM can be done entirely at home, with results in 10 minutes.
So easy, that even a Caveman can do it.
Is AXIM's EUA next?....and if so, why the delay?
In my post coming late next week, I will go into one of my long winded explanations as to why I feel extremely confident that AXIM's EUA is already in the cards. I strongly feel it is not a matter of IF, but rather a matter of WHEN, and as I have already stated in earlier posts, I feel that 2/20/2022 is the latest date for that EUA.
IF I hadn't stumbled across something that has re-directed my attention, AXIM would never have fallen into the teens prior to its EUA, as I had plenty of powder on plenty of bids in the low 20s that would have prevented it.
It wasn't my intention to buy more shares, as I had gone beyond my limits and had accumulated (much) more than intended, but with a few extra dollars just laying around, a huge bargain in the final stretch was certainly not going to go unappreciated.
However, when I stumbled upon something interesting and much less risky, and got the go ahead to shift gears, I pulled all of those bids down. Now, if there is a large dump of shares at market price, and there aren't many others with bids in place to absorb those shares, the teens are a strong possibility.
Dropping into the teens is not pleasant for anyone who is not presently inclined to take advantage of those bargain shares, but it really doesn't make much of a difference in the long run. The pps only matters on the day you sell. Everything else is just what it is.
The downside to a low pps before a pop is that the climb upward is that much harder. It is so much easier to get to $3 from somewhere in the .70s than it is from the .10s. The lower the pps, the harder "We the AXIM shareholders" will have to work and pay attention in order to reap the highest benefits that we can.
Oh....btw, and truly a coincidence as she hasn't come to me with one of those questions in months, my (wife's) daughter came to me tonight with a question about 7 friends who had $28.50 and spent $.50 each on soda, and the remainder on X hotdogs at $1.25 and Y Hamburgers at $2.50....so your earlier post had me warmed up.
Winds up that the answer had to be plotted on an X-Y graph, once you figured out the slop and the Y-intercept, using y = mx + b.
She has a test on it tomorrow, but I think she gets it.
If not, it could be a problem, because I think the smart kid was recently moved to the back of the room..........lol?..........
OMG, I love it!
That's like those math problems that my daughter brings me from time to time.
(10,000 (.25) + 3,000X)/13,000 = .3447, where X = the (average) pps of your shares before today's purchase.
X = .6604
AND, should you buy another 10,000 shares at 10 cents, then
{(10,000(.10) + 13,000(.3447)}/23,000 = y, where y = the new average pps.
Y = .2383
With a total cost for the entire 23,000 shares of $5,480.90 (to check the math, your total purchase to date should have cost $4,480.90).
I often tease my daughter, because the question normally reads, "Utilizing your knowledge of .....", and I read it as, "Utilizing your FATHER'S knowledge of ......"
...but rest assured, I do take the time to teach her how to formulate the problem.
While I do applaud your success today, I personally do not look forward to any future success you might have, because AXIM hitting 10 cents is not something I think I can stomach.............
BTW, as a tease leading up to next week's post, I have STOPPED averaging down on AXIM and have moved future purchases elsewhere....slightly.
I will elaborate more next week. So far my efforts are meeting my exSPACtations exactly as I have anticipated.
Godspeed.
May the tides of the future raise all our boats, and turn them all into yachts!
SUPREME COURT RULES VACCINE MANDATE FOR LARGE BUSINESSES UNCONSTITUTIONAL!
Huge leap forward for Immunopass!
Why?
The mandate would have effected 80+ million Americans.
Without it, what tool can we use to determine one's level of protection against the virus?
The only logical and easiest thing to do is to test one's antibody levels.
And Immunopass is the First-in-Class, at home, Over the Counter, No prescription necessary, easy to use, rapid (10 minutes) results test kit that will be out on the market in the very near future.
There is no other that even comes close. None that have been approved as of yet, and none to be approved after.
Remember: AXIM holds the patent!
NCAA (National College Athletic Association) Quote:
So more and more organizations are going to need the ability to test antibody levels.
Immunopass: Your time has come!